Silence Therapeutics plc (SLNCF)
OTCMKTS
· Delayed Price · Currency is USD
2.250
0.00 (0.00%)
Dec 27, 2024, 3:00 PM EST
Silence Therapeutics Income Statement
Financials in millions GBP. Fiscal year is January - December.
Millions GBP. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 16.25 | 25.38 | 17.5 | 12.42 | 5.48 | 0.24 | Upgrade
|
| Revenue Growth (YoY) | -42.07% | 44.99% | 40.97% | 126.59% | 2145.49% | - | Upgrade
|
| Cost of Revenue | 8.97 | 10.32 | 10.88 | 7.46 | 3.76 | - | Upgrade
|
| Gross Profit | 7.27 | 15.06 | 6.62 | 4.96 | 1.72 | 0.24 | Upgrade
|
| Selling, General & Admin | 20.17 | 20.64 | 19.61 | 20.01 | 13.98 | 9.64 | Upgrade
|
| Research & Development | 45.42 | 44.03 | 35.61 | 30.77 | 20.21 | 13.34 | Upgrade
|
| Other Operating Expenses | - | - | - | - | -1.49 | - | Upgrade
|
| Operating Expenses | 65.59 | 64.66 | 55.21 | 50.77 | 32.7 | 22.98 | Upgrade
|
| Operating Income | -58.32 | -49.6 | -48.59 | -45.81 | -30.98 | -22.73 | Upgrade
|
| Interest Expense | - | -0.03 | -0.05 | -0.01 | -0.02 | -0.03 | Upgrade
|
| Interest & Investment Income | 1.75 | 0.07 | 0.02 | 0.01 | 0.13 | 0.03 | Upgrade
|
| Currency Exchange Gain (Loss) | -10.75 | -2.12 | 1.05 | -0.04 | -5.17 | -0.13 | Upgrade
|
| Other Non Operating Income (Expenses) | 1.38 | 1.38 | 0.2 | - | - | - | Upgrade
|
| EBT Excluding Unusual Items | -65.93 | -50.31 | -47.37 | -45.86 | -36.04 | -22.87 | Upgrade
|
| Pretax Income | -65.93 | -50.31 | -47.37 | -45.86 | -36.04 | -22.87 | Upgrade
|
| Income Tax Expense | -7.07 | -7.04 | -6.88 | -6.45 | -3.49 | -3.29 | Upgrade
|
| Net Income | -58.86 | -43.27 | -40.49 | -39.41 | -32.55 | -19.58 | Upgrade
|
| Net Income to Common | -58.86 | -43.27 | -40.49 | -39.41 | -32.55 | -19.58 | Upgrade
|
| Shares Outstanding (Basic) | 44 | 37 | 32 | 30 | 27 | 25 | Upgrade
|
| Shares Outstanding (Diluted) | 44 | 37 | 32 | 30 | 27 | 25 | Upgrade
|
| Shares Change (YoY) | 21.51% | 15.21% | 8.58% | 8.78% | 8.85% | 6.85% | Upgrade
|
| EPS (Basic) | -1.33 | -1.17 | -1.26 | -1.33 | -1.19 | -0.78 | Upgrade
|
| EPS (Diluted) | -1.33 | -1.17 | -1.26 | -1.33 | -1.19 | -0.78 | Upgrade
|
| Free Cash Flow | -43.95 | -39.4 | -45.6 | 5.5 | -11.29 | 1.72 | Upgrade
|
| Free Cash Flow Per Share | -0.99 | -1.06 | -1.42 | 0.19 | -0.41 | 0.07 | Upgrade
|
| Gross Margin | 44.78% | 59.34% | 37.83% | 39.94% | 31.34% | 100.00% | Upgrade
|
| Operating Margin | -358.97% | -195.48% | -277.66% | -369.02% | -565.49% | -9317.21% | Upgrade
|
| Profit Margin | -362.34% | -170.51% | -231.35% | -317.44% | -594.03% | -8025.41% | Upgrade
|
| Free Cash Flow Margin | -270.53% | -155.25% | -260.53% | 44.26% | -206.00% | 704.10% | Upgrade
|
| EBITDA | -58.01 | -49.27 | -48.28 | -45.56 | -30.49 | -22.25 | Upgrade
|
| EBITDA Margin | - | -194.18% | -275.89% | - | - | - | Upgrade
|
| D&A For EBITDA | 0.31 | 0.33 | 0.31 | 0.25 | 0.5 | 0.48 | Upgrade
|
| EBIT | -58.32 | -49.6 | -48.59 | -45.81 | -30.98 | -22.73 | Upgrade
|
| EBIT Margin | - | -195.48% | -277.66% | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.